References
- Stravitz RT, Lee WM. Acute liver failure. Lancet. 2019; 394(10201):869–881.
- Tan C, Graudins A. Comparative pharmacokinetics of panadol Extend and immediate-release paracetamol in a simulated overdose model. Emerg Med Australas. 2006;18(4):398–403.
- Chiew A, Day P, Salonikas C, et al. The comparative pharmacokinetics of modified-release and immediate-release paracetamol in a simulated overdose model. Emerg Med Australas. 2010;22(6):548–555.
- Chiew AL, Isbister GK, Page CB, et al. Modified release paracetamol overdose: a prospective observational study (ATOM-3). Clin Toxicol. 2018;56(9):810–819.
- Graudins A, Chiew A, Chan B. Overdose with modified-release paracetamol results in delayed and prolonged absorption of paracetamol. Intern Med J. 2010;40(1):72–76.
- Salmonson H, Sjoberg G, Brogren J. The standard treatment protocol for paracetamol poisoning may be inadequate following overdose with modified release formulation: a pharmacokinetic and clinical analysis of 53 cases. Clin Toxicol. 2018;56(1):63–68.
- European Medicines Agency. Modified-release paracetamol-containing products to be suspended from EU market [EMA/118413/2018]. 19 Feb 2018. https://www.ema.europa.eu/medicines/human/referrals/paracetamol-modified-release
- Australian Department of Health, Therapeutic Goods Administration. Final decision in relation to paracetamol (modified release). 26 Aug 2019. https://www.tga.gov.au/book-page/14-final-decision-relation-paracetamol-modified-release
- New Zealand Medicines and Medical Devices Safety Authority. Reclassification of modified-release paracetamol to restricted medicine. 2019. https://www.medsafe.govt.nz/profs/class/Agendas/Agen60/6.5.1-Reclassification-of-Modified-Release-Paracetamol.pdf
- Chiew AL, Reith D, Pomerleau A, et al. Updated guidelines for the management of paracetamol poisoning in Australia and New Zealand. Med J Aust. 2020;212(4):175–183.
- Cairns R, Brown JA, Wylie CE, et al. Paracetamol poisoning-related hospital admissions and deaths in Australia, 2004–2017. Med J Aust. 2019;211(5):218–223.
- Prescott LF. Kinetics and metabolism of paracetamol and phenacetin. Br J Clin Pharmacol. 1980;10(Suppl 2):291s–298s.
- Hayward KL, Powell EE, Irvine KM, et al. Can paracetamol (acetaminophen) be administered to patients with liver impairment? Br J Clin Pharmacol. 2016;81(2):210–222.
- Jaeschke H. Acetaminophen: dose-dependent drug hepatotoxicity and acute liver failure in patients. Dig Dis. 2015;33(4):464–471.
- Davis M, Simmons CJ, Harrison NG, et al. Paracetamol overdose in man: relationship between pattern of urinary metabolites and severity of liver damage. Q J Med. 1976;45(178):181–191.
- Reith D, Medlicott NJ, Kumara De Silva R, et al. Simultaneous modelling of the Michaelis-Menten kinetics of paracetamol sulphation and glucuronidation. Clin Exp Pharmacol Physiology. 2009;36(1):35–42.
- Li J, Chiew AL, Isbister GK, et al. Sulfate conjugation may be the key to hepatotoxicity in paracetamol overdose. Brit Jnl Clinical Pharma. 2021;87(5):2392–2396.
- Allegaert K, Peeters MY, Beleyn B, et al. Paracetamol pharmacokinetics and metabolism in young women. BMC Anesthesiol. 2015;15(1):163.
- Owens KH, Murphy PG, Medlicott NJ, et al. Population pharmacokinetics of intravenous acetaminophen and its metabolites in major surgical patients. J Pharmacokinet Pharmacodyn. 2014;41(3):211–221.
- Jiang S, Madrasi K, Samant T, et al. Population pharmacokinetic modeling of acetaminophen protein adducts in adults and children. J Clin Pharmacol. 2020;60(5):595–604.
- Zhang L, Beal SL, Sheiner LB. Simultaneous vs. sequential analysis for population PK/PD data I: best-case performance. J Pharmacokinet Pharmacodyn. 2003;30(6):387–404.
- Holford NH, Ambros RJ, Stoeckel K. Models for describing absorption rate and estimating extent of bioavailability: application to cefetamet pivoxil. J Pharmacokinet Biopharm. 1992;20(5):421–442.
- Wattanakul T, Teerapong P, Plewes K, et al. Pharmacokinetic properties of intramuscular versus oral syrup paracetamol in Plasmodium falciparum malaria. Malar J. 2016;15:244.
- Shenfield GM. Oral contraceptives. Are drug interactions of clinical significance? Drug Saf. 1993;9(1):21–37.
- Rogers SM, Back DJ, Orme ML. Intestinal metabolism of ethinyloestradiol and paracetamol in vitro: studies using Ussing chambers. Br J Clin Pharmacol. 1987;23(6):727–734.
- GlaxoSmithKline. PANADOL OSTEO modified-release tablet. NEW ZEALAND DATA SHEET. 2020.